Ongoing Projects
-

New cognitive protection strategy to treat epilepsy by preventing the impact of TrkB-FL-mediated cleavage
Funding Entity: Fundação para a Ciência e Tecnologia
Role: Principal Investigator (FMUL)
2025-2028 -

Pan-European Network for Neuroscience Research Infrastructure and Strengthening of Support capacities
Funding Entity: HORIZON Europe, HORIZON-WIDERA-2023-ACCESS-04-01 - Pathways to Synergies, Coordination and Support Action
Consortium involving Faculdade de Medicina da Universidade de Lisboa and Instituto de Medicina Molecular Joao Lobo Antunes (Portugal), Instytut Farmakologii Im. Jerzego Maja Polskiej Akademii Nauk (Poland), The Fundación de Recerca Clínic Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (Spain), and Vilnius University Life Sciences Center (Lithuania).
Role: Member (GIMM)
2024-2026 -

Pacto de Inovação “HfPT – Health from Portugal [Componente 5 do Plano de Recuperação e Resiliência, ao abrigo do concurso no. 02/C05-i01/2022]
Funding Entity: Plano de Recuperação e Resiliência
Role: Principal Investigator (GIMM)
2022-2025 -

TAT-TrkB, a novel neuroprotective compound to fight Alzheimer´s disease
Funding Entity: Santa Casa da Misericórdia
Reference: MB35–2021
Role: Principal Investigator (GIMM)
2021-2025
Past Projects
-

Epileptogenesis & Epilepsy Network
Funding Entity: European Union’s Horizon 2020 research and innovation programme under grant agreement No 952455.
Consortium involving Instituto de Medicina Molecular João Lobo Antunes (iMM), Lisboa, Portugal; Amsterdam Medical Center University of Amsterdam, The Netherlands; Sapienza University of Rome, Italy; University of Lund, Sweeden
Role: Member (GIMM)
2020-2023 -

Novel Therapeutic Strategy and New Biomarker for Alzheimer's disease Based on BDNF Receptor Cleavage
Funding Entity: Santa Casa da Misericórdia
Reference: MB37–2017
Role: Principal Investigator (GIMM)
2017-2020 -

Astrosomes: artificial astrocytes as a novel approach to regulate neuronal communication.
Funding Entity: Fundação para a Ciência e Tecnologia
Reference: PTDC/BTM-SAL/32147/2017
Role: Co-PI (PI: Sandra H. Vaz) (GIMM) -

Adenosine levels reestablishment: new approach for the treatment of Rett Syndrome
Funding Entity: Fundação para a Ciência e Tecnologia
Reference: PTDC/MED-NEU/31929/2017
Role: Coordenator -

CYP46A1 as a new therapeutic target in Niemann-Pick type C disease
Funding Entity: Fundação para a Ciência e Tecnologia
Reference: PTDC/MED-NEU/29455/2017
Role: Researcher (PI: Elsa Rodrigues) -

Regulation of adenosine levels as a new therapeutic strategy for Rett Syndrome
Funding Entity: Association Française du Syndrome de Rett
Role: Coordinator (GIMM) -

Neurologic and Psychiatric Disorders: from synapses to networks (Synanet)
Funding Entity: European Commission, Horizon 2020, Call H2020-TWINN-2015 / H2020-TWINN-2015 - Twinning
Aims to promote collaborative multidisciplinary and translational research by enhancing effective knowledge transfer, exchange of best research practices, and the mobility of early stage researchers between the Instituto de Medicina Molecular (IMM) at the University of Lisbon, the University of Eastern Finland, the University of Rome La Sapienza, and the Lancaster University at UK.
Role: Member (GIMM)
2016-2019 -

Adenosine receptors: new pharmacological targets for the treatment of Rett syndrome.
Funding Entity: Fundação para a Ciência e Tecnologia
Reference: EXPL/BIM-MEC/0009/2013
Role: Coordinator -

Brain Gut interaction- neurotrophic actions
Funding Entity: Nestlé Research Center
Reference: Nestec/IMM/474/2008
Role: Investigator -

Unraveling the effect of different Abeta species upon hippocampal synaptic plasticity and the neuroprotective role of BDNF
Funding Entity: Bayer
Role: Coordinator -

Role of TrkB receptors in ageing
Funding Entity: Gulbenkian Foundation
Role: Co-coordinator -

Purines and control of astrocytes-neurons signalling in rat hippocampal slices and cultured cells
Funding Entity: Fundação para Ciência e Tecnologia
Reference: SFRH/BD/12167/2003
Role: Investigator -

Neurophysiological mechanisms of aging: novel view of old concepts
Funding Entity: Bial Foundation
Reference: PROJ. 57/12
Role: Coordinator -

Study of cytochrome c release induced by Billirubine, Amyloid b-peptide, and Glycochenodeoxycholate
Funding Entity: Fundação para a Ciência e Tecnologia
Reference: PRAXIS/C/SAU/14311/1998
Role: Investigator
Intellectual Property
Trkb-fl based polypeptides and their use in the treatment of alzheimer's disease
Inventor: Maria José de Oliveira Diógenes Nogueira, João Filipe Fonseca Gomes, André Jerónimo Santos, Ana Maria Ferreira de Sousa Sebastião, Carlos Bandeira Duarte
Current Assignee: Faculdade de Medicina da Universidade de Lisboa, Fundação GIMM Gulbenkian Institute For Molecular Medicine, Universidade de Coimbra
Worldwide Application: US (US20230321189A1), CA (CA3177866A1), JP (JP2023521071A), AU (AU2021248268A1), European Patent Office (EP4125999B1)
Classification: A61K38/1787 - Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor; A61P25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia